<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235495</url>
  </required_header>
  <id_info>
    <org_study_id>20060083</org_study_id>
    <secondary_id>U01NS054630</secondary_id>
    <secondary_id>NIH NINDS 5U01 NS040406-08</secondary_id>
    <secondary_id>20060233</secondary_id>
    <nct_id>NCT00235495</nct_id>
  </id_info>
  <brief_title>Albumin in Acute Ischemic Stroke Trial</brief_title>
  <acronym>ALIAS</acronym>
  <official_title>A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neurological Emergencies Treatment Trials Network (NETT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the trial is to determine whether human albumin, administered within 5 hours of
      symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human serum albumin, at 2 g/kg, administered over 2 hours by intravenous infusion, will be
      compared to placebo (isovolumic normal saline) among patients with acute ischemic stroke. All
      patients will have a baseline stroke severity measured as NIH Stroke scale score &gt; 5.
      Patients will treated according to the best standard of care including concurrent treatment
      with intravenous or intra-arterial thrombolysis where appropriate. The primary outcome will
      be determined at 3 months. The primary hypothesis is that, using the composite outcome of a
      modified Rankin score 0-1 or NIH stroke scale score 0-1 at 3 months (or both), the proportion
      of patients with improved outcomes will be greater by 10% or more in the active treatment
      group. [The current trial is termed &quot;Part 2&quot; and incorporates revisions to the initial
      protocol that were instituted after the Data Safety Monitoring Board (DSMB) suspended subject
      recruitment because of a safety concern after 434 subjects had been enrolled. The protocol
      revisions of Part 2 resulted from the study team's thorough review of the Part-1 safety data
      and were designed to optimize safety going forward.]
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment halted by DSMB following interim analysis.
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Favorable Outcome Defined as National Institute of Health Stroke Scale (NIHSS) Score of 0-1 and/or Modified Rankin Scale (mRS) of 0-1.</measure>
    <time_frame>at 3 months</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit. The mRS ranges from 0-6 representing perfect health without symptoms to death. A score of 0 is no symptoms at all and a score of 1 is no significant disability. Able to carry out all usual duties and activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Composite Outcome of mRS 0-1 and/or NIHSS 0-1 and/or Decrease in NIHSS From Baseline by 10 or More Points</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a NIHSS of 0-1 at 24 Hours</measure>
    <time_frame>at 24 hours</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a NIHSS 0-1 at 90 Days.</measure>
    <time_frame>at 90 days</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With a Score on the mRS 0-1 at 90 Days.</measure>
    <time_frame>at 90 days</time_frame>
    <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With a Score on the mRS of 0-2 at 90 Days.</measure>
    <time_frame>at 90 days</time_frame>
    <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Favorable Outcome Per Modified Rankin Scare (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Assessed as the final global disability level on the modified Rankin scale (mRS) at 90 days better than expectation (sliding dichotomy analysis) ) assessed in the intention to treat population.
mRS Scale:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI) 95-100</measure>
    <time_frame>at 90 days</time_frame>
    <description>The Barthel Index (BI) is an ordinal scale used to measure a subject's performance in activities of daily living (ADL) in ten variables - feeding, transfer (bed to chair), grooming, toilet use, bathing, mobility on a level surface, stair use, dressing, bowels and bladder. It is an assessment of independence in ADL and is scored in increments of 5 points. the highest total score for fully independent subjects equals 100. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an EuroQol (EQ-5D) Favorable Score &lt; 0.78</measure>
    <time_frame>at 90 days</time_frame>
    <description>The EQ-5D measures the subject's overall health state in a descriptive system of health-related quality of life (QoL) states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of three responses. The responses record three levels of severity ('no problems', 'some problems', and 'extreme problems) within a particular EQ-5D dimension. The EQ-5D results can be converted to health utility scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Stroke Specific Quality of Life Scale (SSQOL) Score of &gt;=3</measure>
    <time_frame>at 90 days</time_frame>
    <description>Stroke, specific, health-related quality of life (SSQoL) is a self-reported survey that includes 12 domains and 49 items which are scored on a 5pt Likert response format with a lower score indicating worse function/lower ability on that item or domain. Domain scores were calculated as an unweighted average of item scores in that domain. Overall Total Score was calculated as an unweighted average of domain scores. Each Domain Score and the Overall Total Score all range from 1-5 with 1 being worst and 5 being the best. We have presented data here for the number of participants that have an unweighted average of domain scores of 3 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trailmaking A</measure>
    <time_frame>at 90 days</time_frame>
    <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trailmaking B</measure>
    <time_frame>at 90 days</time_frame>
    <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neurological Deterioration Within 48 Hours</measure>
    <time_frame>within 48 hours</time_frame>
    <description>This is assessed as the number of participants with a neurological adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Death Within 7 Days</measure>
    <time_frame>within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Ischemic Stroke Within 30 Days</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Within 48 Hours</measure>
    <time_frame>within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Edema Within 48 Hours</measure>
    <time_frame>within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shortness of Breath Within 48 Hours</measure>
    <time_frame>within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracerebral Hemorrhage (ICH) Within 24 Hours</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic ICH Within 24 Hours</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Within 30 Days</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Within 90 Days</measure>
    <time_frame>within 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">841</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Albumin (ALB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset</description>
    <arm_group_label>Albumin (ALB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>equivalent volume of isotonic saline control</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke

          -  NIH stroke scale score &gt; 5

          -  Age &gt;= 18 and &lt;= 83

          -  ALB or placebo can be administered within 5 hours of symptom onset

          -  ALB or placebo can be administered within 60 minutes of Tissue Plasminogen Activator
             (tPA) administration in the thrombolysis group

          -  Signed informed consent

        Exclusion Criteria:

          -  Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6
             months. An episode of congestive heart failure is any heart failure that required a
             change in medication, diet or hospitalization.

          -  Known valvular heart disease with CHF in the last 6 months.

          -  Severe aortic stenosis or mitral stenosis.

          -  Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG),
             valve replacement surgery) in the last 6 months.

          -  Acute myocardial infarction in the last 6 months.

          -  Signs or symptoms of acute myocardial infarction, including ECG findings, on
             admission.

          -  Baseline elevated serum troponin level on admission (&gt;0.1 mcg/L)

          -  Suspicion of aortic dissection on admission.

          -  Acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic
             instability.

          -  Findings on physical examination of any of the following: (1) jugular venous
             distention (JVP &gt; 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting
             tachycardia (heart rate &gt; 100/min) attributable to congestive heart failure; (4)
             abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to
             congestive heart failure; and/or (6) definite chest x-ray evidence of pulmonary edema.

          -  Current acute or chronic lung disease requiring supplemental chronic or intermittent
             oxygen therapy.

          -  Historical Modified Rankin Score (mRS) ≥2. Patients who live in a nursing home or who
             are not fully independent for activities of daily living immediately prior to the
             stroke are not eligible for the trial.

          -  In-patient stroke. I.e., patients with a stroke occurring as a complication of
             hospitalization for another condition, or as a complication of a procedure.

          -  Planned acute use of intra-arterial (IA) tPA or acute endovascular intervention (e.g.,
             stenting, angioplasty, thrombus retrieval device use) must conform to the following
             criteria: (1) begin within 5 hours of symptom onset, and (2) finish within 7 hours of
             symptom-onset.

          -  Fever, defined as core body temperature &gt; 37.5° C (99.5°F).

          -  Serum creatinine &gt; 2.0 mg/dL or 180 µmol/L.

          -  Profound dehydration.

          -  Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid
             hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on
             the baseline CT or MRI scan.

          -  History of allergy to albumin.

          -  History of latex rubber allergy.

          -  Severe chronic anemia with Hgb &lt; 7.5 g/dL

          -  Pregnancy, breastfeeding or positive pregnancy test. (Women of childbearing age must
             have a negative pregnancy test prior to ALB administration.)

          -  Concurrent participation in any other therapeutic clinical trial.

          -  Evidence of any other major life-threatening or serious medical condition that would
             prevent completion of 3-month follow-up, impair the assessment of outcome, or in which
             ALB therapy would be contraindicated or might cause harm to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron D. Ginsberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D. Hill, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuko Y Palesch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Medical Center-South Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Ctr-Concord</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040-4378</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF-San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center, Davies Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center, Pacific Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O'Connor Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center, Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Ctr-Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida/Shands</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Villages Research Group</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Institute at Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercoastal Neurology/Medical Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Medical Center South</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Hospital</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upper Chesapeake Medical Center</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai-Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Care System/St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute, Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo General Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Med Health and Hospitals</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242-4402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Fairfield Hospital</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Legacy Emmanuel Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Hospital, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Community Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Island Hospital</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H-3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre-University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 7C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 1R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne, Centre de Recherche</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Sante et de Service Sociaux de Chicoutimi</name>
      <address>
        <city>Saguenay</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Hadassah University Hospital</name>
      <address>
        <city>Ein Kerem</city>
        <state>Jerusalem</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center at Tel-Hashomer</name>
      <address>
        <city>Tel Hashomer</city>
        <state>Ramat Gan</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <results_first_submitted>December 12, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Myron Ginsberg</investigator_full_name>
    <investigator_title>Principal Investigator; Peritz Scheinberg Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albumin</title>
          <description>Treatment with 25% Albumin, 2.0 g/kg</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Treatment with same volume of normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="422"/>
                <participants group_id="P2" count="419"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visit/assessmen outside window/missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albumin</title>
          <description>Treatment with 25% Albumin, 2.0 g/kg</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Treatment with same volume of normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="422"/>
            <count group_id="B2" value="419"/>
            <count group_id="B3" value="841"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.42" spread="12.95"/>
                    <measurement group_id="B2" value="64.84" spread="12.88"/>
                    <measurement group_id="B3" value="64.13" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="386"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian/Alaska Native/First Nations People</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="619"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple, Other, or Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oxfordshire Community Stroke Project Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Total Anterior Circulation Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Anterior Circulation Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Posterior Circulation Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lacunar Stroke</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline National Institutes of Health Stroke Scale (NIHSS) Score</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="8" upper_limit="17"/>
                    <measurement group_id="B2" value="11" lower_limit="8" upper_limit="17"/>
                    <measurement group_id="B3" value="11" lower_limit="8" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline ASPECTS</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Baseline ASPECTS &gt;7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ASPECTS &lt;= 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Favorable Outcome Defined as National Institute of Health Stroke Scale (NIHSS) Score of 0-1 and/or Modified Rankin Scale (mRS) of 0-1.</title>
        <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit. The mRS ranges from 0-6 representing perfect health without symptoms to death. A score of 0 is no symptoms at all and a score of 1 is no significant disability. Able to carry out all usual duties and activities.</description>
        <time_frame>at 3 months</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Favorable Outcome Defined as National Institute of Health Stroke Scale (NIHSS) Score of 0-1 and/or Modified Rankin Scale (mRS) of 0-1.</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit. The mRS ranges from 0-6 representing perfect health without symptoms to death. A score of 0 is no symptoms at all and a score of 1 is no significant disability. Able to carry out all usual duties and activities.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of null hypothesis (equal proportions of subjects with NIHSS 0-1 or mRS 0-1 or both at 90 days post-randomization in Albumin and Saline treatment arms) versus alternative hypothesis (greater proportion of subjects with NIHSS 0-1 or mRS 0-1 or both at 90 days post-randomization in Albumin treatment arm).</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Adjusted risk ratio greater than 1 indicates greater risk of good outcome in the Albumin treatment group, while adjusted risk ratio less than 1 indicates greater risk of good outcome in the Saline treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Composite Outcome of mRS 0-1 and/or NIHSS 0-1 and/or Decrease in NIHSS From Baseline by 10 or More Points</title>
        <time_frame>at 3 months</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Composite Outcome of mRS 0-1 and/or NIHSS 0-1 and/or Decrease in NIHSS From Baseline by 10 or More Points</title>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a NIHSS of 0-1 at 24 Hours</title>
        <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
        <time_frame>at 24 hours</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a NIHSS of 0-1 at 24 Hours</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a NIHSS 0-1 at 90 Days.</title>
        <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a NIHSS 0-1 at 90 Days.</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of greater than 20 indicating severe neurologic deficit.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With a Score on the mRS 0-1 at 90 Days.</title>
        <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With a Score on the mRS 0-1 at 90 Days.</title>
          <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With a Score on the mRS of 0-2 at 90 Days.</title>
        <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With a Score on the mRS of 0-2 at 90 Days.</title>
          <description>The mRS ranges from 0-6 representing perfect health without symptoms to death. 0 = No symptoms at all. 1 = No significant disability. Able to carry out all usual duties and activities. 2 = Slight disability. Unable to carry out all previous activities but able to look after own affairs without assistance. 3 = Moderate disability. Requires some help, but able to walk unassisted. 4 = Moderately severe disability. Unable to walk unassisted and unable to attend to own bodily needs without assistance. 5 = Severe disability. Bedridden, incontinent, and requires constant nursing care and attention. 6 = Dead.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Favorable Outcome Per Modified Rankin Scare (mRS)</title>
        <description>Assessed as the final global disability level on the modified Rankin scale (mRS) at 90 days better than expectation (sliding dichotomy analysis) ) assessed in the intention to treat population.
mRS Scale:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.</description>
        <time_frame>90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Favorable Outcome Per Modified Rankin Scare (mRS)</title>
          <description>Assessed as the final global disability level on the modified Rankin scale (mRS) at 90 days better than expectation (sliding dichotomy analysis) ) assessed in the intention to treat population.
mRS Scale:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barthel Index (BI) 95-100</title>
        <description>The Barthel Index (BI) is an ordinal scale used to measure a subject's performance in activities of daily living (ADL) in ten variables - feeding, transfer (bed to chair), grooming, toilet use, bathing, mobility on a level surface, stair use, dressing, bowels and bladder. It is an assessment of independence in ADL and is scored in increments of 5 points. the highest total score for fully independent subjects equals 100. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Barthel Index (BI) 95-100</title>
          <description>The Barthel Index (BI) is an ordinal scale used to measure a subject's performance in activities of daily living (ADL) in ten variables - feeding, transfer (bed to chair), grooming, toilet use, bathing, mobility on a level surface, stair use, dressing, bowels and bladder. It is an assessment of independence in ADL and is scored in increments of 5 points. the highest total score for fully independent subjects equals 100. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BI 95-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otherwise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an EuroQol (EQ-5D) Favorable Score &lt; 0.78</title>
        <description>The EQ-5D measures the subject's overall health state in a descriptive system of health-related quality of life (QoL) states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of three responses. The responses record three levels of severity ('no problems', 'some problems', and 'extreme problems) within a particular EQ-5D dimension. The EQ-5D results can be converted to health utility scores.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an EuroQol (EQ-5D) Favorable Score &lt; 0.78</title>
          <description>The EQ-5D measures the subject's overall health state in a descriptive system of health-related quality of life (QoL) states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of three responses. The responses record three levels of severity ('no problems', 'some problems', and 'extreme problems) within a particular EQ-5D dimension. The EQ-5D results can be converted to health utility scores.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Stroke Specific Quality of Life Scale (SSQOL) Score of &gt;=3</title>
        <description>Stroke, specific, health-related quality of life (SSQoL) is a self-reported survey that includes 12 domains and 49 items which are scored on a 5pt Likert response format with a lower score indicating worse function/lower ability on that item or domain. Domain scores were calculated as an unweighted average of item scores in that domain. Overall Total Score was calculated as an unweighted average of domain scores. Each Domain Score and the Overall Total Score all range from 1-5 with 1 being worst and 5 being the best. We have presented data here for the number of participants that have an unweighted average of domain scores of 3 or greater.</description>
        <time_frame>at 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Stroke Specific Quality of Life Scale (SSQOL) Score of &gt;=3</title>
          <description>Stroke, specific, health-related quality of life (SSQoL) is a self-reported survey that includes 12 domains and 49 items which are scored on a 5pt Likert response format with a lower score indicating worse function/lower ability on that item or domain. Domain scores were calculated as an unweighted average of item scores in that domain. Overall Total Score was calculated as an unweighted average of domain scores. Each Domain Score and the Overall Total Score all range from 1-5 with 1 being worst and 5 being the best. We have presented data here for the number of participants that have an unweighted average of domain scores of 3 or greater.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trailmaking A</title>
        <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
        <time_frame>at 90 days</time_frame>
        <population>Participants were excluded if the Tail Making Test was not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Trailmaking A</title>
          <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
          <population>Participants were excluded if the Tail Making Test was not assessed.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="39" upper_limit="105"/>
                    <measurement group_id="O2" value="56" lower_limit="39" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.913</p_value>
            <method>Wilcoxon rank sum test, normal approx</method>
            <param_type>Rank Sum</param_type>
            <param_value>73098</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trailmaking B</title>
        <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
        <time_frame>at 90 days</time_frame>
        <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Trailmaking B</title>
          <description>The Trail Making Test is a neuropsychological test of visual attention and task switching that is thought to be sensitive to the presence of cerebral dysfunction. It is a timed test consisting of two parts where the subject is asked to draw a &quot;trail&quot; made by connecting numbers in sequential order (part A) and then in part B the combination of numbers and letters. Scoring is calculated separately for Parts A and B but both scores are provided as the minutes and seconds it takes for the subject to complete ach part. Normally, the entire test (A and B) can be completed in 5-10 minutes.</description>
          <population>Intent to Treat population - All subjects randomized into the study are included and analyzed based on the treatment arm to which they were randomized.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="78" upper_limit="173"/>
                    <measurement group_id="O2" value="110" lower_limit="82" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.923</p_value>
            <method>Wilcoxon rank sum test, normal approx</method>
            <param_type>Rank Sum</param_type>
            <param_value>44853.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neurological Deterioration Within 48 Hours</title>
        <description>This is assessed as the number of participants with a neurological adverse event.</description>
        <time_frame>within 48 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neurological Deterioration Within 48 Hours</title>
          <description>This is assessed as the number of participants with a neurological adverse event.</description>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Death Within 7 Days</title>
        <time_frame>within 7 days</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 7 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Death Within 7 Days</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 7 days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Ischemic Stroke Within 30 Days</title>
        <time_frame>within 30 days</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Ischemic Stroke Within 30 Days</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 30 days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Fibrillation Within 48 Hours</title>
        <time_frame>within 48 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Within 48 Hours</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Edema Within 48 Hours</title>
        <time_frame>within 48 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Edema Within 48 Hours</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.37</ci_lower_limit>
            <ci_upper_limit>26.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shortness of Breath Within 48 Hours</title>
        <time_frame>within 48 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Shortness of Breath Within 48 Hours</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 48 hours.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>6.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Intracerebral Hemorrhage (ICH) Within 24 Hours</title>
        <time_frame>within 24 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Intracerebral Hemorrhage (ICH) Within 24 Hours</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 24 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asymptomatic ICH Within 24 Hours</title>
        <time_frame>within 24 hours</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Asymptomatic ICH Within 24 Hours</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 24 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Within 30 Days</title>
        <time_frame>within 30 days</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Death Within 30 Days</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 30 days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Within 90 Days</title>
        <time_frame>within 90 days</time_frame>
        <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 90 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Treatment with 25% Albumin, 2.0 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Treatment with same volume of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Death Within 90 Days</title>
          <population>The safety sample consisted of the 830 subjects who received at least 20% of the indented dose of study-drug. In order to be considered for this analysis, subject must have had the event within the time frame or been followed for at least 90 days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albumin</title>
          <description>Treatment with 25% Albumin, 2.0 g/kg</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Treatment with same volume of normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>SYSTEMIC HEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>NON-CEREBRAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SYMPTOMATIC INTRACRANIAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ASYMPTOMATIC INTRACRANIAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS (STABLE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME - MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;CONGESTIVE HEART FAILURE, PULMONARY EDEMA&quot;</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION OR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION/FLUTTER</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;CONDUCTION BLOCKS (ATRIO-VENTRICULAR BLOCKS, BUNDLE-BRANCH BLOCKS)&quot;</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR ARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEEP VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ARTERIAL EMBOLUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME - UNSTABLE ANGINA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CHEST PAIN (INCLUDING ATYPICAL) WITHOUT MENTION OF CARDIAC ORIGEN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TROPONIN LEAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>VALVULAR HEART DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER CARDIAC ARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER CARDIOVASCULAR DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GASTRIC OR DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>NAUSEA/VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT BLEEDING</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PARALYTIC ILEUS/ BOWEL PSEUDO-OSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BOWEL OSBTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER DIGESTIVE DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>LOCALIZED PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER SYSTEMIC ADVERSE EVENT OR COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER UNCLASSIFIED ADVERSE EVENT</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>OROLINGUAL ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTEREMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SEPTICEMIA OR SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SURGICAL SITE INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CELLULITIS/NON-SURGICAL SKIN INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SURGICAL WOUND HEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER NON-INFECTIOUS SURGICAL WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER ENDOCRINE OR METABOLIC DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT NEOPLASM (EXCEPT SKIN)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>RECURRENT STROKE NOT SPECIFIED AS HEMORRHAGE OR INFARCTION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEPRESSION OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BRAIN ABSCESS OR ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>MENINGITIS OR VENTRICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHEMIC ATTACK</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CEREBRAL EDEMA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="422"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CONFUSION/ENCEPHALOPATHY/DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>INCREASED INTRA-CRANIAL PRESSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PROGRESSION OF STROKE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="422"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER NEUROLOGICAL DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHIATRIC DEPRESSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PSYCHIATRIC DISORDER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER UROGENITAL DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>APNEA OR RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER RESPIRATORY DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCERS/PRESSURE SORES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERTENSION-NOT INTENDED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOTENSION-NOT INTENDED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PRE-CEREBRAL OR CEREBRAL VASCULAR DISEASE (INCLUDING STENOSIS OR OCCLUSION)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SYNCOPE OR PRE-SYNCOPE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;HEMATOMA, NOT OTHERWISE SPECIFIED&quot;</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="352" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="341" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>SEPTICEMIA OR SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SYSTEMIC HEMORRHAGE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>NON-CEREBRAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="422"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>POLYCYTEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER COAGULATION OR HEMATOLOGIC DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RECURRENT STROKE NOT SPECIFIED AS HEMORRHAGE OR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SYMPTOMATIC INTRACRANIAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ASYMPTOMATIC INTRACRANIAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="48" subjects_affected="45" subjects_at_risk="422"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS (STABLE)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME - MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;CONGESTIVE HEART FAILURE, PULMONARY EDEMA&quot;</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION OR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION/FLUTTER</sub_title>
                <counts group_id="E1" events="42" subjects_affected="40" subjects_at_risk="422"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="422"/>
                <counts group_id="E2" events="34" subjects_affected="32" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="422"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;CONDUCTION BLOCKS (ATRIO-VENTRICULAR BLOCKS, BUNDLE-BRANCH BLOCKS)&quot;</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR ARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CHEST PAIN (INCLUDING ATYPICAL) WITHOUT MENTION OF CARDIAC ORIGEN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TROPONIN LEAK</sub_title>
                <counts group_id="E1" events="53" subjects_affected="51" subjects_at_risk="422"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>VALVULAR HEART DISEASE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER CARDIAC ARRHYTHMIAS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="422"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER CARDIOVASCULAR DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="422"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL VASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="422"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GASTRITIS/ ESOPHAGITIS/GERD</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GASTRIC OR DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>NAUSEA/VOMITING</sub_title>
                <counts group_id="E1" events="81" subjects_affected="70" subjects_at_risk="422"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT BLEEDING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="422"/>
                <counts group_id="E2" events="51" subjects_affected="48" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FECAL INCONTINENCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PARALYTIC ILEUS/ BOWEL PSEUDO-OSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BOWEL OSBTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER DIGESTIVE DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="422"/>
                <counts group_id="E2" events="49" subjects_affected="38" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="422"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>LOCALIZED PAIN</sub_title>
                <counts group_id="E1" events="73" subjects_affected="54" subjects_at_risk="422"/>
                <counts group_id="E2" events="78" subjects_affected="55" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>GENERALIZED PAIN</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER SYSTEMIC ADVERSE EVENT OR COMPLICATION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="422"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EDEMA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER UNCLASSIFIED ADVERSE EVENT</sub_title>
                <counts group_id="E1" events="49" subjects_affected="40" subjects_at_risk="422"/>
                <counts group_id="E2" events="54" subjects_affected="40" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>&quot;HEPATITIS, JAUNDICE, OR LIVER FAILURE&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>OROLINGUAL ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ALLERGIC REACTION TO STUDY DRUG</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTEREMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="422"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>UPPER REPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="81" subjects_affected="73" subjects_at_risk="422"/>
                <counts group_id="E2" events="83" subjects_affected="72" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CELLULITIS/NON-SURGICAL SKIN INFECTION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL DISSECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CRANIAL NERVE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>INFILTRATION OF IV SITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SURGICAL SITE INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SURGICAL WOUND HEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER NON-INFECTIOUS SURGICAL WOUND COMPLICATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL TRAUMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="422"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>EKG ABNORMALITIES</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>LIVER ENZYMES ELEVATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER ENZYME/S ELEVATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FLUID OVERLOAD ALONE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="422"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DIABETES INSIPIDUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERNATREMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="99" subjects_affected="93" subjects_at_risk="422"/>
                <counts group_id="E2" events="72" subjects_affected="66" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERCALCEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="422"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ACID-BASE IMBALANCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOCHLOREMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERCHLOREMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER ENDOCRINE OR METABOLIC DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="47" subjects_affected="36" subjects_at_risk="422"/>
                <counts group_id="E2" events="63" subjects_affected="42" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT NEOPLASM (EXCEPT SKIN)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM (SKIN)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEPRESSION OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CEREBRAL EDEMA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="92" subjects_affected="81" subjects_at_risk="422"/>
                <counts group_id="E2" events="84" subjects_affected="76" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="422"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>INCREASED INTRA-CRANIAL PRESSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PROGRESSION OF STROKE</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER NEUROLOGICAL DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="38" subjects_affected="31" subjects_at_risk="422"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION/ENCEPHALOPATHY/DELIRIUM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="422"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PSYCHIATRIC DEPRESSION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="422"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="422"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PSYCHIATRIC DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="422"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>UROGENITAL INCONTINENCE (WAS 410)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER UROGENITAL DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="422"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CRAMPING</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOXEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERCARBIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>CRACKLES/RALES</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>APNEA OR RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TACHYPNEA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SHORTNESS OF BREATH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="422"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>OTHER RESPIRATORY DISORDER OR COMPLICATION</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="422"/>
                <counts group_id="E2" events="49" subjects_affected="36" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ITCHING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCERS/PRESSURE SORES</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>DEEP VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SUPERFICIAL VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPERTENSION-NOT INTENDED</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="422"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>HYPOTENSION-NOT INTENDED</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="422"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>PRE-CEREBRAL OR CEREBRAL VASCULAR DISEASE (INCLUDING STENOSIS OR OCCLUSION)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHEMIC ATTACK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>SYNCOPE OR PRE-SYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>&quot;HEMATOMA, NOT OTHERWISE SPECIFIED&quot;</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Myron D. Ginsberg</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-6103</phone>
      <email>MGinsberg@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

